PT4103178T - Métodos de tratamento da doença de fabry - Google Patents

Métodos de tratamento da doença de fabry

Info

Publication number
PT4103178T
PT4103178T PT217536069T PT21753606T PT4103178T PT 4103178 T PT4103178 T PT 4103178T PT 217536069 T PT217536069 T PT 217536069T PT 21753606 T PT21753606 T PT 21753606T PT 4103178 T PT4103178 T PT 4103178T
Authority
PT
Portugal
Prior art keywords
treatment methods
fabry disease
fabry
disease
treatment
Prior art date
Application number
PT217536069T
Other languages
English (en)
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of PT4103178T publication Critical patent/PT4103178T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/42Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4848Monitoring or testing the effects of treatment, e.g. of medication
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PT217536069T 2020-02-10 2021-02-10 Métodos de tratamento da doença de fabry PT4103178T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062972392P 2020-02-10 2020-02-10

Publications (1)

Publication Number Publication Date
PT4103178T true PT4103178T (pt) 2026-03-30

Family

ID=77272302

Family Applications (1)

Application Number Title Priority Date Filing Date
PT217536069T PT4103178T (pt) 2020-02-10 2021-02-10 Métodos de tratamento da doença de fabry

Country Status (11)

Country Link
US (1) US20210251972A1 (pt)
EP (2) EP4732901A2 (pt)
JP (1) JP2023513700A (pt)
KR (1) KR20220150902A (pt)
AU (1) AU2021218578A1 (pt)
CA (1) CA3167476A1 (pt)
DK (1) DK4103178T3 (pt)
FI (1) FI4103178T3 (pt)
LT (1) LT4103178T (pt)
PT (1) PT4103178T (pt)
WO (1) WO2021163183A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3224546C (en) 2017-05-30 2026-02-24 Amicus Therapeutics, Inc. Use of migalastat in the treatment of fabry patients
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
US12594268B2 (en) * 2018-08-20 2026-04-07 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
TW202408513A (zh) * 2016-07-19 2024-03-01 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症

Also Published As

Publication number Publication date
CA3167476A1 (en) 2021-08-19
LT4103178T (lt) 2026-04-10
EP4732901A2 (en) 2026-04-29
FI4103178T3 (fi) 2026-03-23
EP4103178A1 (en) 2022-12-21
DK4103178T3 (da) 2026-03-30
EP4103178B1 (en) 2025-12-24
AU2021218578A1 (en) 2022-08-25
US20210251972A1 (en) 2021-08-19
EP4103178A4 (en) 2024-03-20
KR20220150902A (ko) 2022-11-11
WO2021163183A1 (en) 2021-08-19
JP2023513700A (ja) 2023-04-03

Similar Documents

Publication Publication Date Title
PT4103178T (pt) Métodos de tratamento da doença de fabry
JP1742637S (ja) 医療用撮像機
EP4091530A4 (en) Medical system
CL2021000047S1 (es) Masajeador.
IL291362A (en) Treatment of syngap1 encephalopathy
EP3843716A4 (en) METHODS OF TREATMENT OF LYSOSOMAL STORAGE DISEASES
EP4382023A4 (en) Endoscope
PT3773558T (pt) Tratamento combinado de doença artrítica
EP4493175A4 (en) MIRDAMETINIB TREATMENT
EP3630101A4 (en) METHODS OF TREATMENT OF FIBROTIC DISEASES
EP4391884A4 (en) ENDOSCOPE
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
EP4312708A4 (en) ENDOSCOPE
PT3952858T (pt) Método de tratamento de tumores
EP4247229A4 (en) ENDOSCOPE SYSTEM
EP4037684A4 (en) Medicinal cognitive treatments
IL286646A (en) Compositions, devices and methods for treating fabry disease
EP4069438C0 (en) SKIN TREATMENT SYSTEM
EP4117655A4 (en) Treatment methods
EP4405465A4 (en) TREATMENT METHODS
EP4401721A4 (en) CANCER TREATMENT
EP4356127A4 (en) THERAPEUTIC OLIGONUCLEOTIDE METHODS
EP4458205A4 (en) COMB
IL300152A (en) Methods of treatment using furosemide
EP4174556A4 (en) Endoscope